Managing Recruitment When You're Running Twelve Studies at Once

The real problem isn't volume, it's collision

When a site runs eight or twelve studies at once, recruitment rarely fails because there weren't enough leads. It fails because two protocols competed for the same patient, a coordinator spent Tuesday on the study that was loudest instead of the one that was closest to a milestone, and nobody noticed a study had gone three weeks without a single new pre-screen.

Managing a concurrent portfolio is a triage discipline. Here's how to build it.

Map overlap before the study activates

As soon as a new protocol is awarded, sit down with the inclusion/exclusion criteria of everything already open and write out where they collide. In most site portfolios the overlaps cluster predictably:

• Same indication, different line of therapy. Your type 2 diabetes database feeds four studies with different A1c bands and washout requirements.
• Shared exclusion. One study excludes prior biologic exposure; another actively wants it. That's actually good news — it's a clean split.
• Competing burden. Two trials both need weekly visits for the first month. Even an eligible patient can only take one.

Produce a one-page routing rule: if a caller has X, they go to Study A first; if they fail on Y, they cascade to Study B. Post it where the phones are answered. Routing decided in advance is routing that survives a busy afternoon.

Rank studies weekly, not once

Every study wants to be the priority. Give the portfolio an explicit weekly ranking based on three things:

1. Distance to a contractual or competitive deadline — enrollment caps that will close, sponsor deadlines, competitive enrollment races.
2. Slots remaining versus weeks remaining. A study needing four patients in six weeks outranks one needing eight in nine months.
3. Screen-fail rate. A protocol where two of three consented patients fail needs a much bigger funnel to hit the same number.

Re-rank in a fifteen-minute Monday meeting. When priorities shift, say so out loud — coordinators guessing at priorities is how studies quietly stall.

Give every study a named owner and a floor

Spreading recruitment across the whole team sounds efficient and usually isn't. Assign each protocol one owner accountable for its funnel. Then set a floor: a minimum weekly activity that happens regardless of ranking — say, ten chart reviews or five outreach calls. Deprioritized doesn't mean dormant. Floors prevent the slow-death pattern where a mid-tier study gets zero attention for a month and then needs heroics.

Watch the leading indicators per study

Enrollment numbers tell you about last month. Track per study, weekly:

• New qualified pre-screens
• Pre-screen to consent conversion
• Days from first contact to screening visit
• Screen fail reasons, grouped

When one study's pre-screen count drops for two consecutive weeks, that's the intervention point — not when you miss the milestone. Sites commonly find that the slowest metric across a portfolio isn't lead volume but time-to-schedule, which is a staffing and calendar problem, not a marketing one.

Protect visit capacity as hard as you protect leads

A portfolio can be over-recruited relative to exam rooms, phlebotomy coverage, or a single sub-investigator's signature availability. Before you increase outreach for any study, confirm you can absorb the screening visits within two weeks. Generating leads you can't schedule burns patient goodwill and inflates your no-show rate across every study you run.

Say no early

The most useful portfolio tool is declining a study that would cannibalize an existing one. Sponsors respect a site that explains the overlap during feasibility far more than one that signs and then under-enrolls both.